Paul N Meyer
Overview
Explore the profile of Paul N Meyer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
793
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Caponetti G, Dave B, Perry A, Smith L, Jain S, Meyer P, et al.
Leuk Lymphoma
. 2015 Apr;
56(11):3082-9.
PMID: 25827211
In this study, we investigated the significance of MYC, BCL2 and BCL6 gene abnormalities in a cohort of 205 diffuse large B-cell lymphoma (DLBCL) patients studied by conventional and/or fluorescence...
2.
Taverna J, Babiker H, Yun S, Bishop M, Lau-Braunhut S, Meyer P, et al.
Biomark Res
. 2015 Jan;
2(1):23.
PMID: 25635225
Paraneoplastic syndromes can precede the initial manifestation and diagnosis of cancer. Paraneoplastic syndromes are a heterogeneous group of disorders caused by mechanisms other than the local presence of tumor cells....
3.
Johnson N, Slack G, Savage K, Connors J, Ben-Neriah S, Rogic S, et al.
J Clin Oncol
. 2012 Aug;
30(28):3452-9.
PMID: 22851565
Purpose: Diffuse large B-cell lymphoma (DLBCL) is curable in 60% of patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). MYC translocations, with or without BCL2 translocations, have...
4.
Perry A, Cardesa-Salzmann T, Meyer P, Colomo L, Smith L, Fu K, et al.
Blood
. 2012 Jun;
120(11):2290-6.
PMID: 22740447
Biologic factors that predict the survival of patients with a diffuse large B-cell lymphoma, such as cell of origin and stromal signatures, have been discovered by gene expression profiling. We...
5.
Iqbal J, Meyer P, Smith L, Johnson N, Vose J, Greiner T, et al.
Clin Cancer Res
. 2011 Sep;
17(24):7785-95.
PMID: 21933893
Purpose: We have previously shown the prognostic significance of BCL2 expression in the activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL) patients treated with cyclophosphamide-Adriamycin-vincristine-prednisone (CHOP) or CHOP-like therapy. However, after...
6.
Meyer P, Fu K, Greiner T, Smith L, Delabie J, Gascoyne R, et al.
Am J Clin Pathol
. 2010 Dec;
135(1):54-61.
PMID: 21173124
The cellular composition of the tumor microenvironment may affect survival in diffuse large B-cell lymphoma (DLBCL). We performed immunostains for 2 stromal cell markers, CD68 and SPARC (secreted protein, acidic...
7.
Meyer P, Fu K, Greiner T, Smith L, Delabie J, Gascoyne R, et al.
J Clin Oncol
. 2010 Dec;
29(2):200-7.
PMID: 21135273
Purpose: Patients with diffuse large B-cell lymphoma (DLBCL) can be divided into prognostic groups based on the cell of origin of the tumor as determined by microarray analysis. Various immunohistochemical...
8.
Meyer P, Cao Y, Jacobson K, Krausz T, Flanigan R, Picken M
Diagn Mol Pathol
. 2008 Apr;
17(3):141-4.
PMID: 18382368
Morphologic overlap between chromophobe renal cell carcinoma (ChRCC) and renal oncocytomas (RO) has been widely recognized. Whether these tumors are genetically related and represent a spectrum of benign to malignant...
9.
Meyer P, Roychowdhury S, Kini A, Alkan S
Leuk Res
. 2007 Jul;
32(1):143-9.
PMID: 17617451
The effects of a novel heat shock protein inhibitor, 17AAG, on established APL cell lines (NB4 and R1) were analyzed. 17AAG induces apoptosis in APL cell lines both sensitive (NB4)...
10.
Meyer P, Clark J, Flanigan R, Picken M
Am J Clin Pathol
. 2007 Jun;
128(1):70-9.
PMID: 17580272
Renal cell carcinomas associated with Xp11.2 translocations ( TFE3 gene fusions) are rare tumors predominantly reported in children. We studied 5 cases of translocation carcinoma in adult patients, 18 years...